Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.40 |
| ▸ | TUBB | P07437 | 3/20 | 0.40 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.40 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.40 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.40 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.40 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.40 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.40 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.40 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.40 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.40 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.40 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.40 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.40 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7729500 | 0.93 | ALDH1A1 (0.40) | LPAR2ABL1ALDH1A1MAPK1HSD17B10 | |
| SCHEMBL8144435 | 0.86 | CACNA1G (0.40) | MAPK1SMN1; SMN2TDP1CYP1A2CYP3A4 | |
| SCHEMBL7729028 | 0.86 | SMYD3 (0.41) | ABL1TDP1RAF1BRAFTSHR | |
| SCHEMBL7722055 | 0.85 | LPAR2 (0.44) | LPAR2ABL1ALDH1A1MAPK1HSD17B10 | |
| SCHEMBL7731211 | 0.84 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL21436230 | 0.84 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL7732752 | 0.82 | GID4 (0.41) | ABL1MAPK1TDP1LMNATSHR | |
| SCHEMBL7730867 | 0.81 | MEN1 (0.42) | POLBLMNAMEN1KMT2A | |
| SCHEMBL7730864 | 0.81 | MEN1 (0.42) | POLBLMNAMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7729677 | 0.80 | MEN1 (0.41) | POLBLMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11419834-B2 | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide | RHODE ISLAND HOSPITAL (US) | 2022-08-23 | — | — | US | disclosed |
| US-20210137948-A1 | TREATMENT OF INFECTIONS CAUSED BY NEISSERIA GONOCOCCUS USING A HALOGENATED SALICYLANILIDE | UNION therapeutics A/S (DK) | 2021-05-13 | — | — | US | disclosed |
| EP-3773602-A1 | TREATMENT OF INFECTIONS CAUSED BY NEISSERIA GONOCOCCUS USING A HALOGENATED SALICYLANILIDE | UNION therapeutics A/S (DK) | 2021-02-17 | — | — | EP | disclosed |
| US-20200268693-A1 | METHODS FOR TREATING DISEASES OR INFECTIONS CAUSED BY OR ASSOCIATED WITH H. PYLORI USING A HALOGENATED SALICYLANILIDE | RHODE ISLAND HOSPITAL | 2020-08-27 | — | — | US | disclosed |
| US-20190328687-A1 | Antibacterial Compounds | VICTORIA LINK LIMITED (NZ) | 2019-10-31 | — | — | US | disclosed |
| WO-2019192968-A1 | TREATMENT OF INFECTIONS CAUSED BY NEISSERIA GONOCOCCUS USING A HALOGENATED SALICYLANILIDE | UNION therapeutics A/S (DK) | 2019-10-10 | — | — | WO | disclosed |
| EP-3220919-A1 | ANTIBACTERIAL COMPOUNDS | Victoria Link Limited (NZ) | 2017-09-27 | — | — | EP | disclosed |
| WO-2016080846-A1 | ANTIBACTERIAL COMPOUNDS | COPP JANINE NAOMI (NZ) | 2016-05-26 | — | — | WO | disclosed |
| US-6399629-B1 | PYRROLIDINES AND PIPERIDINES FOR TREATING MICROBIAL INFECTIONS BY REDUCING EXPORT OF COADMINISTERED ANTIMICROBIAL AGENT OR COMPOUND SYNTHESIZED BY MICROBES FOR THEIR GROWTH; REDUCING IN VIVO AVAILABILITY | MICROCIDE PHARMACEUTICALS, INC. | 2002-06-04 | — | — | US | disclosed |
| WO-2000001714-A1 | EFFLUX PUMP INHIBITORS | MICROCIDE PHARMACEUTICALS, INC. (US) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200268693-A1 | METHODS FOR TREATING DISEASES OR INFECTIONS CAUSED BY OR ASSOCIATED WITH H. PYLORI USING A HALOGENATED SALICYLANILIDE | MALT1, SI, BCL6 | LPAR2 3257/4885ABL1 233/4885ALDH1A1 2423/4885 |
| US-11419834-B2 | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide | MALT1, SI, BCL6 | LPAR2 3257/4885ABL1 233/4885ALDH1A1 2423/4885 |
| US-20210137948-A1 | TREATMENT OF INFECTIONS CAUSED BY NEISSERIA GONOCOCCUS USING A HALOGENATED SALICYLANILIDE | MGLL, NIT2, SI | LPAR2 1784/4885ABL1 2795/4885ALDH1A1 2698/4885 |
| US-20190328687-A1 | Antibacterial Compounds | SHARPIN, FDPS, BROX | LPAR2 4227/4885ABL1 730/4885ALDH1A1 1387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.